Market closed
Royalty Pharma/$RPRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Royalty Pharma
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Ticker
$RPRX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
-
Website
Royalty Pharma Metrics
BasicAdvanced
$11B
Market cap
10.00
P/E ratio
$2.55
EPS
0.47
Beta
$0.84
Dividend rate
3.29%
Dividend yield
Price and volume
Market cap
$11B
Beta
0.47
52-week high
$31.66
52-week low
$24.05
Average daily volume
3.4M
Dividend rate
$0.84
Financial strength
Current ratio
1.536
Quick ratio
1.532
Long term debt to equity
64.439
Total debt to equity
74.157
Dividend payout ratio (TTM)
32.50%
Interest coverage (TTM)
7.46%
Management effectiveness
Return on assets (TTM)
5.69%
Return on equity (TTM)
17.28%
Valuation
Price to earnings (TTM)
10.001
Price to revenue (TTM)
5.053
Price to book
1.66
Price to tangible book (TTM)
1.66
Price to free cash flow (TTM)
-53.897
Dividend yield (TTM)
3.29%
Forward dividend yield
3.29%
Growth
Revenue change (TTM)
-2.51%
Earnings per share change (TTM)
518.56%
3-year revenue growth (CAGR)
-0.29%
3-year earnings per share growth (CAGR)
9.87%
3-year dividend per share growth (CAGR)
7.94%
What the Analysts think about Royalty Pharma
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Royalty Pharma stock.
Royalty Pharma Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Royalty Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Royalty Pharma News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Royalty Pharma stock?
Royalty Pharma (RPRX) has a market cap of $11B as of December 31, 2024.
What is the P/E ratio for Royalty Pharma stock?
The price to earnings (P/E) ratio for Royalty Pharma (RPRX) stock is 10 as of December 31, 2024.
Does Royalty Pharma stock pay dividends?
Yes, the Royalty Pharma (RPRX) stock pays dividends to shareholders. As of December 31, 2024, the dividend rate is $0.84 and the yield is 3.29%. Royalty Pharma has a payout ratio of 32.5% on a trailing twelve-month basis.
When is the next Royalty Pharma dividend payment date?
The next Royalty Pharma (RPRX) dividend payment date is unconfirmed.
What is the beta indicator for Royalty Pharma?
Royalty Pharma (RPRX) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.